Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Post by mdjbrownon Jan 30, 2024 11:17am
110 Views
Post# 35852630

In July 2023 the Company entered into

In July 2023 the Company entered intoan additional supply agreement with a top tier generic pharmaceutical company in Brazil. 

In Medipharms Q2 Presentation they mention:

BRAZIL FY’23 market value estimate: $70 million USD million (IQVIA & MediPharm)

• Only Canadian Company with drug product approval in Brazil
• High barrier to entry with each product registration requiring 18 to 32 months
• Partners include large multinational pharmaceutical companies, such as Active Pharmaceutica  
 
https://assets-global.website-files.com/61ba7048400e00d31e087120/64376bc4e5f0df438be8a2dd_2023_MediPharm-Investor-Deck-April2023%20%20Final%20Copy.pdf



Is Active Pharmaceutica the top tier partner, as they were acquired in June 2021 by Caldic BM who in turn were taken over by Advent International?
 
  https://www.caldic.com/en/News/Caldic-Latin-America-fully-integrated-and-rebranded-to-further-unlock-value-creation

<< Previous
Bullboard Posts
Next >>